Company / Operating Income
FATE THERAPEUTICS INC Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$210.3M
FY2025
5-year range
-$308.4M / -$100.7M
FY2021-FY2025
Trend
-10.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$308M to -$210M over the past 2 years.
Based on SEC 10-K filings.
-$210M in FY2025.
Improved from -$308M to -$210M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 10.4% year-over-year.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$210.3M | -10.4% |
| FY2024 | -$190.5M | +38.2% |
| FY2023 | -$308.4M | -140.8% |
| FY2022 | -$128.1M | -27.2% |
| FY2021 | -$100.7M | -50.1% |
| FY2020 | -$67.1M | -59.3% |
| FY2019 | -$42.1M | -31.8% |
| FY2018 | -$32.0M | -15.0% |
| FY2017 | -$27.8M | -11.6% |
| FY2016 | -$24.9M | -40.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026